Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVEH - Ives Health Company -- Ignore unavailable to you. Want to Upgrade?

To: jmhollen who wrote (8)	2/20/2001 11:30:13 PM
From: peter michaelson	Read Replies (2) \| Respond to of 54

From IVEH 10KSB for 1999 On August 24, 1998, the Company entered into a License Agreement to the rights to certain technology known as (1) the T-Factor Immune System Optimizer and (2) The Burn Treatment Therapy. The rights to the technology were acquired for future development of the technology for the consumer market. The rights to the license, which included a royalty provision to the seller and extends through August 24, 2049, were acquired for approximately $25,000. The cost related to the license and rights were capitalized and is being amortized over five years.